Epicrispr secures $90M after early data on epigenetic FSHD treatment

Epicrispr Biotechnologies has raised $90 million for its Series C round after sharing promising early data around a potential new way to treat a rare muscle disease called facioscapulohumeral muscular dystrophy. The Series C was ...